Date Modified: March 31, Clinical Quality Measures for PQRS

Similar documents
Date Modified: May 29, Clinical Quality Measures for PQRS

Non-QPP Measures. # Measure Title Definition Type Domain. Cryptorchidism: Inappropriate use of scrotal/groin ultrasound on boys

creatinine lab order placed abdomen, MRI abdomen, ultrasound abdomen ordered or performed

Non-QPP Measures 3 AQUA12. 6 AQUA15 Stones: Urinalysis documented 30 days before

Percentage of patients who underwent endoscopic procedures following SWL

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

MEASURE SPECIFICATIONS

MEASURE SPECIFICATIONS

Prostate Cancer Dashboard

Cancer Endorsement Maintenance 2011-Maintenance Measures

2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures

IQSS 2019 QCDR and MIPS Measure Specifications

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2014 Oncology Measures Group Overview

Possible Denominator Codes Applicable to OMS * Le Fort Fractures 21346, 21347, 21348, 21422, 21423, 21432, 21433, 21435, 21436

NATIONAL QUALITY FORUM

Identifying Initial Populations and Sampling for OCM and EBRT. Henrietta C. Hight, BA, BSN, RN, CCM, CDMS, CPHQ Quality Improvement Specialist

One Stop Prostate Biopsy Protocol Author Consultation Date Approved

Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care

2014 Physician Quality Reporting System Data Collection Form: Oncology (for patients aged 18 and older)

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care

Michigan Urological Surgery Improvement Collaborative

Best Papers. F. Fusco

AQUA Registry 2019 Non-QPP Measure Specifications. Denominator Exceptions. IPSS<8 None None Yes Patient Reported Outcome (PRO)

Case Discussions: Prostate Cancer

Screening and Diagnosis Prostate Cancer

Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer

Clinical Quality Measures for PQRS. Last Updated: June 4, 2014

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer

Navigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News

The NOF & NBHA Quality Improvement Registry

The European Board of Urology

Prostate Overview Quiz

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations

THE UROLOGY GROUP

2015 Physician Quality Reporting System Data Collection Form: Oncology (for patients aged 18 and older)

Patients who receive image or palpation-guided needle biopsy (core or FNA) for the diagnosis of breast cancer.

Prostatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD

How do I control (monitor) patients receiving TRT after prostate cancer treatment

March 31, Dear colleagues,

Radiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008

2015 PQRS Registry. Source Measure Title Measure Description CITIUS1

Oncology Quality Clinical Data Registry

Troubleshooting Audio

Clinical Case Conference

Measures Groups Specifications Manual

Diagnosis and management of prostate cancer in the

Compass PTN Core Measures

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.

Personalized Therapy for Prostate Cancer due to Genetic Testings

Genomics and Genetic Testing. Copyright 2017 Myriad Genetics, Inc., all rights reserved.

Measure Name: Prostate Cancer: Cancer Surveillance Owner: NQF (#625) Steward: Active Health Management

Prostate MRI: Who needs it?

Effective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18

Measure #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination

Commissioning Urology Services in New NHS

Technology appraisal guidance Published: 21 November 2018 nice.org.uk/guidance/ta546

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer. Project Overview Ronald C. Chen, MD MPH

Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA

Consensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease

Attachment #2 Overview of Follow-up

2016 Physician Quality Reporting System Data Collection Form: Sinusitis (for patients aged 18 and older)

Prostate Cancer: 2010 Guidelines Update

A schematic of the rectal probe in contact with the prostate is show in this diagram.

Measure #72 (NQF 0385): Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients National Quality Strategy Domain: Effective Clinical Care

Meaningful Use Clinical Quality Measures for Eligible Professionals

Prostate Cancer Case Study 1. Medical Student Case-Based Learning

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline High-Risk Disease

THE HISTORY AND EVOLUTION OF PROSTATE CANCER DIAGNOSIS AND TREATMENT BY: DR. ANDREW GROLLMAN ALBUQUERQUE UROLOGY ASSOCIATES

EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924

To treat or not to treat: When to treat! A case presentation

Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer

MR-US Fusion Guided Biopsy: Is it fulfilling expectations?

MEDICAL POLICY. SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER POLICY NUMBER: CATEGORY: Technology Assessment

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

Active surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation

Subject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49

Radical Prostatectomy:

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease

Department of Urology, Cochin hospital Paris Descartes University

Physician Self-Referral: Recent Research from the Government Accountability Office (GAO)

National Prostate Cancer Audit. Bill Cross June 2015

Guideline Prostate cancer: diagnosis and management (update)

Prostate Cancer in men with germline DNA repair deficiency

MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of

Focal Therapy is a Fool s Paradise : The whole prostate must be treated!

NPQR Quality Payment Program (QPP) Measures 21_18247_LS.

2017 Merit-based Incentive Payment System. Avoiding the Penalty

PET imaging of cancer metabolism is commonly performed with F18

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy

American College of Physicians Genesis Registry

Measure ID Domain Measure Title Measure Description/Definition Numerator Denominator Denominator Exclusions Denominator Exceptions

Radical prostate surgery?

Transcription:

Date Modified: March 31, 2015 2015 Clinical Quality s for PQRS

# Domain Title Description Type Denominator Numerator Denominator Exclusions/Exceptions 1 Patient Safety Prostate Biopsy Antibiotic Process Compliance 2 Effective Clinical Care Prostate Biopsy: Unplanned Hospital Admission within 30 Days of TRUS Biopsy 3 Effective Clinical Care Prostate Biopsy: Cancer Detection on Initial Prostate Biopsy 4 Community/Population Health Prostate Biopsy: Proportion of patients undergoing a prostate biopsy with a PSA < 4 5 Effective Clinical Care Prostate Biopsy: Repeat Biopsy for Patients with Atypical Small Acinar Proliferation (ASAP) 102 Efficiency and Cost Reduction 6 Efficiency and Cost Reduction Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients Prostate Cancer: Avoidance of Overuse of CT Scan for Staging Low Risk Prostate Cancer Patients 104 Effective Clinical Care Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients Compliance with AUA best practices for antibiotic prophylaxis for transrectal ultrasound-guided (TRUS) biopsy Percentage of biopsies where patients aged 30 years and older had an unplanned hospital admission within 30 days of biopsy Proportion of patients undergoing initial prostate biopsy in the registry found to have Proportion of patients undergoing a prostate biopsy with a PSA < 4 Proportion of patients undergoing a repeat prostate biopsy within 12 months of their initial biopsy in the registry as a result of a finding of atypical small acinar proliferation (ASAP) as per the NCCN guidelines Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a CT scan performed at any time since diagnosis of prostate cancer Percentage of patients, regardless of age, with a diagnosis of prostate cancer at high risk of recurrence receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist) Process # of prostate biopsies for patients aged 30 or older # of prostate biopsies for patients aged 30 or older # of patients aged 30 or older undergoing a prostate biopsy # of patients aged 30 or older undergoing a prostate biopsy # of patients aged 30 or older that had a finding of ASAP on their initial prostate biopsy Process Process # of low-risk patients 30 years or older receiving brachytherapy, EBRT, RP, or cryotherapy Process # of biopsies where a compliant antibiotic regimen was given # of biopsies where a hospital admission resulted within 30 days of the procedure # of patients that have an initial biopsy in the registry which shows # of patients undergoing a prostate biopsy with a PSA < 4 # of patients undergoing a repeat prostate biopsy as a result of a finding of ASAP on their initial biopsy See # of low risk patients receiving brachytherapy, EBRT, RP, or cryotherapy who did not have a CT scan since diagnosis of See Non-TRUS biopsies; biopsies performed in patients < 30 years of age; biopsies performed in patients that have Biopsies performed in patients < 30 years of age; biopsies performed in patients that have treatment for treatment for treatment for treatment for Prostate cancer patients < 30 years of age; patients receiving an alternate form of treatment from those specified; patients that have treatment for Rationale evidence-based care safety of medical care clinical effectiveness appropriate utilization of prostate biopsy evidence-based care appropriate resource utilization Michigan Urological Surgery Improvement Collaborative (MUSIC) QCDR Page 1

# Domain Title Description Type Denominator Numerator Denominator Exclusions/Exceptions 130 Patient Safety Documentation of Current Process See Medications in the Medical Record 194 Effective Clinical Care Oncology: Cancer Stage Documented 250 Effective Clinical Care Radical Prostatectomy Pathology Reporting 265 Communication and Care Coordination Biopsy Follow-Up 7 Effective Clinical Care Prostate Cancer: Active Surveillance for Low Risk Prostate Cancer Patients 8 Effective Clinical Care Prostate Cancer: Radical Prostatectomy Cases LOS 9 Communication and Care Coordination Prostate Cancer: Unplanned Hospital Readmission After Radical Prostatectomy Percentage of visits for patients aged 18 years and older for which the eligible professional attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-thecounters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND must contain the medications name, dosage, frequency and route of administration. Percentage of patients, regardless of age, with a diagnosis of cancer who are seen in the ambulatory setting who have a baseline American Joint Committee on Cancer (AJCC) cancer stage or documentation that the cancer is metastatic in the medical record at least once during the 12 month reporting period Percentage of radical prostatectomy pathology reports that include the pt category, the pn category, the Gleason score and a statement about margin status Percentage of new patients whose biopsy results have been reviewed and communicated to the primary care/referring physician and patient by the performing physician Proportion of patients with low-risk receiving active surveillance Percentage of radical prostatectomy cases with a length of stay > 2 days Percentage of patients aged 30 years and older who had an unplanned hospital readmission within 30 days of principal procedure Process Process Process # of low-risk patients 30 or older # of patients aged 30 or older who underwent a radical prostatectomy as treatment for # of radical prostatectomies for patients aged 30 or older See See See # of low-risk patients on active surveillance # of patients with a length of stay > 2 days after radical prostatectomy # of radical prostatectomies where a hospital admission resulted within 30 days of the procedure treatment for ; patients that are not being screened or treated for treatment for treatment for treatment for ; patients that are not being screened or treated for prostate cancer Prostate cancer patients < 30 years of age; patients that have Prostate cancer patients < 30 years of age; patients that have Prostatectomies performed in patients < 30 years of age; treatment for Rationale patientcentered decision making appropriate resource utilization safety of medical care Michigan Urological Surgery Improvement Collaborative (MUSIC) QCDR Page 2

Non-PQRS #1: Prostate Biopsy Antibiotic Compliance Compliance with AUA best practices for antibiotic prophylaxis for transrectal ultrasound-guided (TRUS) biopsy Patient safety # of biopsies where a compliant antibiotic regimen was given # of prostate biopsies for patients aged 30 or older Excludes non-trus biopsies; biopsies performed in patients < 30 years of age; biopsies performed in treatment for evidence-based care Non-PQRS # 2: Prostate Biopsy: Unplanned Hospital Admissions within 30 days of TRUS Biopsy Percentage of biopsies where patients aged 30 years and older had an unplanned hospital admission within 30 days of biopsy Effective clinical care # of biopsies where a hospital admission resulted within 30 days of the procedure # of prostate biopsies for patients aged 30 or older Excludes non-trus biopsies; biopsies performed in patients < 30 years of age; biopsies performed in treatment for safety of medical care Michigan Urological Surgery Improvement Collaborative (MUSIC) QCDR Page 3

Non-PQRS # 3: Prostate Biopsy: Cancer Detection on Initial Prostate Biopsy Proportion of patients undergoing initial prostate biopsy in the registry found to have Effective clinical care # of patients that have an initial biopsy in the registry which shows # of patients aged 30 or older undergoing a prostate biopsy Excludes non-trus biopsies; biopsies performed in patients < 30 years of age; biopsies performed in treatment for clinical effectiveness Non-PQRS # 4: Prostate Biopsy: Proportion of patients undergoing a prostate biopsy with a PSA < 4 Proportion of patients undergoing a prostate biopsy with a PSA < 4 Community/Population Health # of patients undergoing a prostate biopsy with a PSA < 4 # of patients aged 30 or older undergoing a prostate biopsy Excludes non-trus biopsies; biopsies performed in patients < 30 years of age; biopsies performed in treatment for appropriate utilization of prostate biopsy Michigan Urological Surgery Improvement Collaborative (MUSIC) QCDR Page 4

Non-PQRS # 5: Prostate Biopsy: Repeat Biopsy for Patients with Atypical Small Acinar Proliferation (ASAP) Proportion of patients undergoing a repeat prostate biopsy within 12 months of their initial biopsy in the registry as a result of a finding of atypical small acinar proliferation (ASAP) as per the NCCN guidelines Effective Clinical Care # of patients undergoing a repeat prostate biopsy as a result of a finding of ASAP on their initial biopsy # of patients undergoing a repeat prostate biopsy as a result of a finding of ASAP on their initial biopsy Excludes non-trus biopsies; biopsies performed in patients < 30 years of age; biopsies performed in treatment for evidence-based care Non-PQRS # 6: Prostate Cancer: Avoidance of Overuse of CT Scan for Staging Low Risk Prostate Cancer Patients Percentage of patients, regardless of age, with a diagnosis of at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a CT scan performed at any time since diagnosis of Efficiency and cost reduction # of low risk patients receiving brachytherapy, EBRT, RP, or cryotherapy who did not have a CT scan since diagnosis of # of low-risk patients 30 years or older receiving brachytherapy, EBRT, RP, or cryotherapy Excludes patients < 30 years of age; patients receiving an alternate form of treatment from those specified; patients that have appropriate resource utilization Michigan Urological Surgery Improvement Collaborative (MUSIC) QCDR Page 5

Non-PQRS # 7: Prostate Cancer: Active Surveillance for Low Risk Prostate Cancer Patients Proportion of patients with low-risk receiving active surveillance Effective clinical care # of low-risk patients on active surveillance # of prostate biopsies for patients aged 30 or older Excludes patients < 30 years of age; treatment for patient-centered decision making Non-PQRS # 8: Prostate Cancer: Radical Prostatectomy Cases LOS Percentage of radical prostatectomy cases with a length of stay > 2 days Effective clinical care # of patients with a length of stay > 2 days after radical prostatectomy # of patients aged 30 or older who underwent a radical prostatectomy as treatment for Excludes patients < 30 years of age; treatment for appropriate resource utilization Michigan Urological Surgery Improvement Collaborative (MUSIC) QCDR Page 6

Non-PQRS # 9: Prostate Cancer: Unplanned Hospital Readmission After Radical Prostatectomy Percentage of patients aged 30 years and older who had an unplanned hospital readmission within 30 days of principal procedure Communication and care coordination # of radical prostatectomies where a hospital admission resulted within 30 days of the procedure # of radical prostatectomies for patients aged 30 or older Excludes prostatectomies performed in patients < 30 years of age; treatment for safety of medical care Michigan Urological Surgery Improvement Collaborative (MUSIC) QCDR Page 7